The ongoing debate between the use of recombinant/synthetic biomarkers or endogenous biomarkers to generate quality control samples has been leaning toward endogenous biomarkers. Read on to see how ultrasensitive immunoassays, such as Single Molecule Counting (SMC®) assays, enable the precise and accurate measurement of endogenous inflammation biomarkers.
There has been much discussion on the use of recombinant/synthetic biomarkers vs endogenous biomarkers to generate quality control (QC) samples. The clinical biomarker community has accepted that endogenous biomarker quality controls (EQC) are “real” sample quality controls that best represent clinical samples in comparison to spiked QCs made with recombinant biomarkers that often do not represent clinical samples. Furthermore, numerous publications have shown that EQCs perform differently than recombinant spiked QCs, supporting the use of EQCs over spiked QCs in biomarker analysis.
Despite this fact, many scientists in the biomarker community will still use spiked QCs in preference over EQCs. This is often an attempt to mimic pharmacokinetic (PK) bioanalytical practices that create QCs by spiking manmade manufactured drug molecules into the blank matrix. Our research emphasizes that biomarker analysis should always be on how the patient samples perform in the assay rather than implementing PK practices into the assay.
IL-17 family and pathway are targets for several novel therapies being developed for the treatment of autoimmune diseases. They play multiple roles in both acute and chronic inflammation. The IL-17 pathway is inducted by invasive pathogens such as pro-inflammatory cytokines and it attracts immune cells to the site of inflammation. Here, its actions are protective.
However, the pathway is also activated in chronic inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, and multiple sclerosis. Here, it actually assists in the tissue destruction process.
Ultrasensitive immunoassay technology, Single Molecule Counting (SMC®) technology, can be used to measure endogenous inflammation biomarkers. Specifically, the IL-17 pathway was analyzed with the SMC® Human Interleukin 17A (IL-17A) Immunoassay Kit and the SMC® Human Interleukin 17F (IL-17F) Immunoassay Kit in the poster and webinar highlighted below on this page.
Results confirmed that whole blood samples could be stimulated to produce endogenous biomarker molecules ex vivo. These samples proved to be a valuable tool to use in method characterization and critical components of method verification experiments (e.g., parallelism). Data showed an excellent correlation between two detection platforms with the IL-17 SMC® assays showing commutability of methods if required.
For Research Use Only. Not For Use In Diagnostic Procedures.
To continue reading please sign in or create an account.Don't Have An Account?